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understanding of nonesmall cell lung cancer (NSCLC).
What was once thought of as a single common disease has
emerged as a collection of relatively uncommon diseases
with different genetic drivers,1 and the recognition of
distinct molecular subtypes of NSCLC has led to the rapid
adoption of new targeted drugs for the treatment of patients
with epidermal growth factor receptor (EGFR) gene muta-
tions and EML4/ALK gene rearrangements. Although
personalized therapy is a worthy goal, the need to identify
appropriate patients for molecularly targeted therapy has
introduced multiple issues that need to be addressed by both
pathologists and treating oncologists. Which NSCLC
patients should be tested, how quickly must testing be
performed, and when should that testing be performed in the
disease process? What techniques are most appropriate,
what are the tissue requirements for testing, and how should
scarce tissue be prioritized? In an attempt to standardize
practices and provide guidance on these issues, the College
of American Pathologists (CAP), the International Associ-
ation for the Study of Lung Cancer (IASLC), and the
Association for Molecular Pathology (AMP) have jointly
issued a guideline for the selection of lung cancer patients
for EGFR and ALK testing that should provide a framework
for molecular testing going forward.2
The need for such a guideline is evident given the
rapidity of change in this ﬁeld. In 2004, multiple groups
independently identiﬁed recurring mutations in the tyrosine
kinase domain of the EGFR gene in patients having notable
clinical responses to the EGFR inhibitor geﬁtinib3,4; in
2009, the Iressa Pan-Asian Study (IPASS) reported that
EGFR tyrosine kinase inhibitors (TKIs) were superior to
chemotherapy in this targeted population.5 The evidence of
clinical beneﬁt in this population was strong enough that inCopyright ª 2013 American Society for Investigative Pathology
and the Association for Molecular Pathology.
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a Provisional Clinical Opinion recommending routine
testing for EGFR mutations in all NSCLC patients being
considered for ﬁrst-line treatment with an EGFR TKI.6 The
CAP, IASLC, and AMP guideline expands on this recom-
mendation with more detailed descriptions of who should
be tested (all patients with adenocarcinomas and mixed
tumors), when (at diagnosis), and how (left in large part up
to the discretion of the local site). The guideline makes it
clear that upfront EGFR mutation testing is a top priority,
and it also explores important but less well-understood
topics, such as which lesions (primary versus metastatic)
to biopsy for testing and testing in the situation of acquired
resistance.
In 2007, Soda et al7 identiﬁed the EML4/ALK fusion gene
in 7% of the NSCLC patients they examined, and only 4 years
later in 2011 the US Food and Drug Administration approved
crizotinib to treat patients with ALK-rearranged NSCLC.8
Unlike EGFR TKIs, crizotinib can only be used when the
presence of the target has been conﬁrmed, and its approval
was accompanied by a US Food and Drug Administratione
approved companion diagnostic test (break-apart ﬂuores-
cence in situ hybridization probes for ALK rearrangement
detection). Practically overnight, pathology departments had
to begin testing for ALK using the approved assay but with
little guidance until now as to who should be tested and what
Guest Editorialtissue was appropriate for testing. The CAP, IASLC, and
AMP guideline again recommends testing at diagnosis for all
patients with adenocarcinomas and mixed tumors and inter-
estingly allows immunohistochemical (IHC) screening for
ALK IHC-positive patients whose diagnosis can then be
conﬁrmed by ﬂuorescence in situ hybridization. On the basis
of a higher rate of prevalence in NSCLC patients, EGFR
testing should be prioritized ﬁrst when tissue is scarce and
then ALK testing performed if tissue is available. Both tests
should have results available within 2 weeks, which is the
maximum time that would still be clinically useful.
In 2013, a histologic diagnosis of lung cancer made by
the anatomical pathologist is only the ﬁrst step, and further
testing by the molecular pathologist now plays a key role in
diagnosis and determination of treatment. Molecular testing
for EGFR mutations and ALK rearrangements has become
the accepted standard of care, and the CAP, IASLC, and
AMP guideline provides a comprehensive resource to help
institutions as they work to provide this important service
for their patients. The guideline is very well supported by
the data in its recommendations for upfront testing and
provides a framework that can be easily updated as new
targeted therapies emerge that require molecular testing. The
pace at which drugs are being tested based on selection for
the presence of a molecular target is only accelerating, with
multiple new target-drug combinations currently in trials.9,10
The guideline also contains suggestions that are less well
supported by the literature, such as testing patients with
early-stage disease at the time of resection and testing for
mechanisms of acquired resistance. These suggestions are
certainly reasonable but raise questions of cost in the current
environment of value-based care. These issues certainly
merit discussion, however, and the guideline provides
a venue for these issues to be aired and discussed until more
information emerges from clinical studies.
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